International Patent: USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN PREPARING ANTI-TUMOR MEDICAMENT

GENEVA, July 18 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/071523) for “USE OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN PREPARING ANTI-TUMOR MEDICAMENT”. With publication no. WO/2026/149507, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 47/68

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....